Skip to main content
SpringerLink
Log in

Optimal versus maximally tolerated dose in cancer chemotherapy treatment

  • Editorial
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz M, Jones RB, Shpall EJ, Bast RC, Cilbert CJ, Oette DH (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869–876

    PubMed  Google Scholar 

  • Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388–395

    PubMed  Google Scholar 

  • Crown J, Wasserheit C, Hakes T, Fennelly D, Reich L, Moore M, Schneider J, Curtin, Rubin SC, Reichman B, Moore M, Yao TJ, Gilewski T, Gulati S, Markman M, Norton L (1992) Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derved hematopoietic progenitor cells. J Natl Cancer Inst 84:1935–1936

    PubMed  Google Scholar 

  • Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748–1753

    PubMed  Google Scholar 

  • Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yogoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422

    PubMed  Google Scholar 

  • Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805

    PubMed  Google Scholar 

  • Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS (1989) A phase II trial of taxol in metastatic melanoma. Cancer 65:2478–2481

    Google Scholar 

  • McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279

    PubMed  Google Scholar 

  • Morstyn G, Burgess AW (1988) Hemopoietic growth factors: A review. Cancer Res 48:5624–5637

    PubMed  Google Scholar 

  • Murphy WK, Fossella FV, Winn J, Shin DM, Hynes E, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384–387

    PubMed  Google Scholar 

  • Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259

    PubMed  Google Scholar 

  • Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093–4100

    PubMed  Google Scholar 

  • Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E (1992) Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165–1170

    PubMed  Google Scholar 

  • Seidman A, Reichman B, Crown J, Begg C, Heelan R, Hakes T, Surbone A, Gilewski T, Lebwohl D, Currie V, Hudis C, Klecker R, Collins J, Toomasi F, Berkery R, Quinlivan S, Kelsen D, Norton L (1992) Activity of taxol with recombinant granulocyte colony stimulating factor (GCSF) as first chemotherapy of patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 11:59

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 44195, Cleveland, Ohio, USA

    Maurie Markman

  2. Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, 44195, Cleveland, Ohio, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the author

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Optimal versus maximally tolerated dose in cancer chemotherapy treatment. J Cancer Res Clin Oncol 119, 576–577 (1993). https://doi.org/10.1007/BF01372720

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01372720

Search

Navigation